Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report

Matthew J. Barth, Stanton Goldman, Lynette M Smith, Sherrie Perkins, Bruce Shiramizu, Thomas G. Gross, Lauren Harrison, Warren Sanger, Mark B. Geyer, Lisa Giulino-Roth, Mitchell S. Cairo

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m2) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t1/2 of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t1/2.

Original languageEnglish (US)
Pages (from-to)678-683
Number of pages6
JournalBritish Journal of Haematology
Volume162
Issue number5
DOIs
StatePublished - Sep 1 2013

Fingerprint

B-Cell Leukemia
B-Cell Lymphoma
Pharmacokinetics
Drug Therapy
Safety
Rituximab

Keywords

  • CD20
  • Non-Hodgkin lymphoma
  • Pediatric
  • Pharmacokinetics
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia : A Children's Oncology Group report. / Barth, Matthew J.; Goldman, Stanton; Smith, Lynette M; Perkins, Sherrie; Shiramizu, Bruce; Gross, Thomas G.; Harrison, Lauren; Sanger, Warren; Geyer, Mark B.; Giulino-Roth, Lisa; Cairo, Mitchell S.

In: British Journal of Haematology, Vol. 162, No. 5, 01.09.2013, p. 678-683.

Research output: Contribution to journalArticle

Barth, MJ, Goldman, S, Smith, LM, Perkins, S, Shiramizu, B, Gross, TG, Harrison, L, Sanger, W, Geyer, MB, Giulino-Roth, L & Cairo, MS 2013, 'Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report', British Journal of Haematology, vol. 162, no. 5, pp. 678-683. https://doi.org/10.1111/bjh.12434
Barth, Matthew J. ; Goldman, Stanton ; Smith, Lynette M ; Perkins, Sherrie ; Shiramizu, Bruce ; Gross, Thomas G. ; Harrison, Lauren ; Sanger, Warren ; Geyer, Mark B. ; Giulino-Roth, Lisa ; Cairo, Mitchell S. / Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia : A Children's Oncology Group report. In: British Journal of Haematology. 2013 ; Vol. 162, No. 5. pp. 678-683.
@article{e33821b7fe8141478bdfecdd25ae8984,
title = "Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report",
abstract = "The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m2) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t1/2 of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t1/2.",
keywords = "CD20, Non-Hodgkin lymphoma, Pediatric, Pharmacokinetics, Rituximab",
author = "Barth, {Matthew J.} and Stanton Goldman and Smith, {Lynette M} and Sherrie Perkins and Bruce Shiramizu and Gross, {Thomas G.} and Lauren Harrison and Warren Sanger and Geyer, {Mark B.} and Lisa Giulino-Roth and Cairo, {Mitchell S.}",
year = "2013",
month = "9",
day = "1",
doi = "10.1111/bjh.12434",
language = "English (US)",
volume = "162",
pages = "678--683",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia

T2 - A Children's Oncology Group report

AU - Barth, Matthew J.

AU - Goldman, Stanton

AU - Smith, Lynette M

AU - Perkins, Sherrie

AU - Shiramizu, Bruce

AU - Gross, Thomas G.

AU - Harrison, Lauren

AU - Sanger, Warren

AU - Geyer, Mark B.

AU - Giulino-Roth, Lisa

AU - Cairo, Mitchell S.

PY - 2013/9/1

Y1 - 2013/9/1

N2 - The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m2) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t1/2 of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t1/2.

AB - The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m2) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t1/2 of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t1/2.

KW - CD20

KW - Non-Hodgkin lymphoma

KW - Pediatric

KW - Pharmacokinetics

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84881663487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881663487&partnerID=8YFLogxK

U2 - 10.1111/bjh.12434

DO - 10.1111/bjh.12434

M3 - Article

C2 - 23802659

AN - SCOPUS:84881663487

VL - 162

SP - 678

EP - 683

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -